Molecular data in the clinical setting can have transformative impact by reducing cost of care and improving outcomes. Increased efficiencies and accuracy in reporting molecular diagnostics are critical to achieve the results that patients, pathologists and oncologists demand.
- $604 million in annual savings among all patients when Panitumamab or Cetuximab is limited to metastatic colorectal cancer patients whose KRAS gene is not mutated.1
- 74% reduction in the risk of death or disease progression in melanoma patients with BRAF V600E mutation when taking targeted therapy compared to standard of care.2
- 75% increase in personalized medicine investment by industry from 2006-2011.3